MacroGenics Inventory 2012-2024 | MGNX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

MacroGenics inventory from 2012 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

MacroGenics inventory from 2012 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$199.9B
Stryker (SYK)	$137.7B
Boston Scientific (BSX)	$121.6B
Medtronic (MDT)	$113B
EssilorLuxottica (ESLOY)	$104.4B
Haleon (HLN)	$48.1B
Lonza Group Ag (LZAGY)	$45.4B
ResMed (RMD)	$35B
Koninklijke Philips (PHG)	$29B
Terumo (TRUMY)	$27.9B
Zimmer Biomet Holdings (ZBH)	$21.6B
Baxter (BAX)	$20.1B
Insulet (PODD)	$16.6B
Smith & Nephew SNATS (SNN)	$13.4B
Bio-Rad Laboratories (BIO)	$9.5B
Demant (WILYY)	$9.2B
BellRing Brands (BRBR)	$7.7B
Lantheus Holdings (LNTH)	$7.5B
ICU Medical (ICUI)	$4.3B
TG Therapeutics (TGTX)	$3.9B
Haemonetics (HAE)	$3.9B
Perrigo (PRGO)	$3.8B
GN Store Nord (GNNDY)	$3.8B
Neogen (NEOG)	$3.7B
Prestige Consumer Healthcare (PBH)	$3.6B
Envista Holdings (NVST)	$3.3B
QuidelOrtho (QDEL)	$3.1B
Agios Pharmaceuticals (AGIO)	$2.6B
Maravai LifeSciences Holdings (MRVI)	$2.3B
Green Thumb Industries (GTBIF)	$2.2B